|
Gene: EOGT |
Gene summary for EOGT |
Gene summary. |
Gene information | Species | Human | Gene symbol | EOGT | Gene ID | 285203 |
Gene name | EGF domain specific O-linked N-acetylglucosamine transferase | |
Gene Alias | AER61 | |
Cytomap | 3p14.1 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q5NDL2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
285203 | EOGT | HCC1_Meng | Human | Liver | HCC | 1.64e-08 | 5.23e-03 | 0.0246 |
285203 | EOGT | S014 | Human | Liver | HCC | 1.43e-04 | 2.05e-01 | 0.2254 |
285203 | EOGT | S015 | Human | Liver | HCC | 6.19e-03 | 1.92e-01 | 0.2375 |
285203 | EOGT | S016 | Human | Liver | HCC | 5.75e-03 | 1.74e-01 | 0.2243 |
285203 | EOGT | S027 | Human | Liver | HCC | 1.05e-04 | 4.24e-01 | 0.2446 |
285203 | EOGT | S028 | Human | Liver | HCC | 8.42e-19 | 5.07e-01 | 0.2503 |
285203 | EOGT | S029 | Human | Liver | HCC | 1.02e-20 | 6.37e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:001821011 | Liver | HCC | peptidyl-threonine modification | 71/7958 | 125/18723 | 8.68e-04 | 5.14e-03 | 71 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EOGT | SNV | Missense_Mutation | rs767580080 | c.750N>G | p.Phe250Leu | p.F250L | Q5NDL2 | protein_coding | deleterious(0) | benign(0.286) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EOGT | SNV | Missense_Mutation | novel | c.587N>G | p.Ser196Cys | p.S196C | Q5NDL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.625) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EOGT | SNV | Missense_Mutation | novel | c.1065C>G | p.Ile355Met | p.I355M | Q5NDL2 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EOGT | SNV | Missense_Mutation | c.466G>A | p.Ala156Thr | p.A156T | Q5NDL2 | protein_coding | deleterious(0.03) | benign(0.388) | TCGA-EW-A1OY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
EOGT | SNV | Missense_Mutation | novel | c.1447C>T | p.Pro483Ser | p.P483S | Q5NDL2 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EOGT | SNV | Missense_Mutation | novel | c.841N>A | p.Gly281Arg | p.G281R | Q5NDL2 | protein_coding | tolerated(0.4) | probably_damaging(0.914) | TCGA-S3-A6ZG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
EOGT | insertion | Nonsense_Mutation | novel | c.421_422insATTTTTGAGGTCAAACGTCCATGCCAAGGCCAGGAATG | p.Ser141AsnfsTer3 | p.S141Nfs*3 | Q5NDL2 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
EOGT | deletion | Frame_Shift_Del | novel | c.581delN | p.Leu194Ter | p.L194* | Q5NDL2 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
EOGT | SNV | Missense_Mutation | rs541573152 | c.1408C>T | p.Arg470Trp | p.R470W | Q5NDL2 | protein_coding | deleterious(0) | possibly_damaging(0.85) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EOGT | SNV | Missense_Mutation | rs587776995 | c.1130N>A | p.Arg377Gln | p.R377Q | Q5NDL2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |